Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an update.
On March 1, 2026, bioAffinity Technologies presented new research at the American Academy of Allergy, Asthma and Immunology annual meeting in Philadelphia showing its sputum-based diagnostic platform can identify antibody drug receptors for leading asthma therapies, including dupilumab and benralizumab. The poster detailed how this approach could help physicians match asthma and COPD patients to the most effective biologic treatments and track inflammatory changes over time.
The work extends bioAffinity’s established CyPath® Lung technology, which already supports early lung cancer detection, into the broader respiratory disease market. By demonstrating the ability to guide personalized therapy selection and improve disease monitoring, the findings highlight a potential new clinical application and revenue avenue for the company, while underscoring its strategy to use noninvasive sputum diagnostics to enhance outcomes and reduce healthcare costs in asthma and COPD care.
The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage cancer and other lung diseases, with a particular emphasis on lung cancer detection. Its first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed through subsidiary Precision Pathology Laboratory Services to identify early lung cancer in high-risk patients using flow cytometry and AI-driven analysis.
CyPath® Lung employs a fluorescent porphyrin to highlight cancer and cancer-related cells and has demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients with small indeterminate lung nodules. The company aims to leverage its proprietary flow cytometry and automated AI platform to expand into additional diagnostic tests that support personalized treatment decisions and improved disease monitoring for lung-related conditions.
Average Trading Volume: 145,613
Technical Sentiment Signal: Sell
Current Market Cap: $4.77M
See more insights into BIAF stock on TipRanks’ Stock Analysis page.